Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | PHASE2 | COMPLETED | 44 | — | — | Nov 1, 2003 | Sep 1, 2007 | Jun 4, 2009 | 3 | United States |
| Name | Type | Description |
|---|---|---|
| TOCOSOL Paclitaxel | DRUG | - |
Inclusion Criteria: * Histologic diagnosis of transitional cell carcinoma (TCC) of the urothelium including bladder, renal pelvis, ureter, or urethra * Stage IV disease * One and only one prior systemic cytotoxic chemotherapy regimen administered as adjuvant or neoadjuvant chemotherapy or to treat ...